38 results about "Refractory Disease" patented technology

The present invention provides therapeutic agents for neuropathic pain, the agents having excellent therapeutic effects on neuropathic pain, which is an intractable disorder. More specifically, the invention provides therapeutic agents for neuropathic pain comprising, as the active ingredient, an opioid receptor antagonist (particularly naloxone, naltrexone, naloxonazine, naltrindole, etc.), pharmaceutical compositions for treating neuropathic pain comprising an opioid receptor antagonist as the active ingredient, and a method for treating neuropathic pain using opioid receptor antagonists.

The invention relates to a kukoamine B salt, a preparation method thereof and a purpose of the kukoamine B salt in preparation of medicines for preventing and treating sepsis. Experiments show that the kukoamine B salt has a good inhibition effect on main pathogenic factors mediating the sepsis and can be used to prepare medicines for preventing and treating the sepsis. The kukoamine B salt and various pharmaceutically acceptable carriers and / or diluents can be prepared into various preparations, so an efficient control means is provided for such intractable diseases on condition that definite and effective sepsis treatment measures are clinically lacked at present.

The invention discloses a high selenium and germanium broccoli, and belongs to the technical field of high-tech production of vegetable crops in soilless culture superposed with industrial greenhouse bases. The high selenium and germanium broccoli consists of selenium and germanium enriching spirulina ganderma capense mineral elements, an excellent organic fertilizer: deodorizing environment-friendly enzymes of vegetable and fruit peels fermented by human and animal manure, a fertility enhancer, liquid waste winery using human and animal manure and a composite element nutritional base fertilizer for cultivating broccoli. In production of broccoli, the technology of the industrial greenhouse bases superposed with soilless culture is mainly adopted. Based on outstanding characteristics of root application and foliage spray, the pertinence is strong, oxygen is quick to absorb and transfer, the fixing effect of soil to some nutrients can be avoided, and the utilization ratio of the nutrients is improved. Insufficient fertilizer absorption by the root system can be supplemented by foliage spray, and the yield-increasing effect is remarkable. The content of copper poly-enzyme molecules in broccoli is increased. The broccoli is homological of medicine and food to effectively protect myocardial cells and promote spontaneous recovery of cells in the whole body, and has better treatment or assistant treatment effect on chronic diseases and various refractory diseases.

Belonging to the technical field of bio-medicine, the invention discloses a spleen immune factor and its preparation method. The spleen immune factor or specific spleen immune factor is prepared through an ultrafiltration or dialysis method. With a molecular weight less than 20000 Dalton, the spleen immune factor of the invention has proteins absent in a transfer factor as well as high bioactivity. Development and application of the spleen immune factor provided in the invention not only expands the utilization efficiency of animal (chicken, pig etc.) spleen resources, enhances the bioactivity of a spleen extract, but also provides a preparation raw material characterized by easily available crude materials, low cost and no toxic and side effect and used for treating human as well as animal refractory diseases like bird flu and tumors, etc. Therefore, the spleen immune factor of the invention is suitable for industrial production.

The present invention relates to a class of proteins, a process of production thereof, and a method for treatment of neurological and viral diseases in humans and animals. More specifically it applies to the treatment of heretofore intractable diseases such as retro-viral infections including human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) and equine acquired immunodeficiency virus (EAIV). The

The invention discloses a compound combined medicine for treating ulcerative colitis. The compound combined medicine is prepared from the following components in parts by weight: 2-9 parts of coptis chinensis, 6-15 parts of scutellaria baicalensis, 10-30 parts of patrinia, 6-20 parts of fried angelica sinensis, 5-20 parts of parched white peony roots, 5-15 parts of raw garden burnets, 5-20 parts of lithospermum, 5-15 parts of madders, 6-15 parts of radix angelicae, 3-12 parts of simmered elecampane and 2-6 parts of raw liquorice. The invention further discloses a preparation method and application of the ompound combined medicine. The invention provides an effective therapeutic medicine for treating the refractory diseases ulcerative colitis and is economical and practical and broad in clinical application prospect. The compound combined medicine is simple in preparation method, simple, fast, efficient and easy to operate, and prepared granules are convenient to carry and take.

The invention relates to a method for constructing a cell transplantation slice by using human umbilical cord mesenchymal stem cells (hUC-MSCs) and anthropogenic amniotic membrane. The method comprises the following steps: taking the freshly collected anthropogenic amniotic membrane and umbilical cord, separating chorion from the amniotic membrane, treating the separated amniotic membrane by normal saline, and then cryopreserving for later use; cutting the umbilical cord into small pieces, and tearing Wharton's jelly off; cutting the Wharton's jelly into pieces, putting the cut Wharton's jelly onto a sterile culture vessel, adding a culture solution into the sterile culture vessel, and putting the sterile culture vessel into an incubator for culturing to obtain primary generation hUC-MSCs; adding pancreatin into a culture medium of the primary generation hUC-MSCs, digesting, and continuously culturing in the incubator to obtain the hUC-MSCs; carrying out sterile hydration on the cryopreserved standby amniotic membrane, then flatly laying the amniotic membrane on an amniotic membrane carrier thimble, and then moving into the sterile culture vessel; inoculating the hUC-MSCs in the culture vessel, and then culturing in the incubator to obtain the cell transplantation slice with cell confluence reaching up to 80-90%. The cell transplantation slice prepared by the method is capable of carrying out damage repair at specific parts, so that the defects of using the hUC-MSCs or amniotic membrane alone for treatment are overcome; therefore, a new treatment strategy is provided for refractory diseases, and a new therapy approach is opened up for the clinical application of stem cells.

The invention relates to nano element anion far infrared fabric underwear for curing diabetes mellitus, belonging to the technical field of producing functional healthy textile garment underwear. Diabetes mellitus is an endocrine metabolic system whole-life disease, and diabetics need to take medicines or take an injection every day, thus bringing great pain, annoyance and inconvenience for people. In the invention, the fiber fabric underwear prepared from nano Se or organic Se, chromium gluconate, SiO2, TiO2, ZnO, Al2O3 and the like as well as a traditional Chinese medicine nano mixture of medical stone and tourmaline, far infrared finishing agent JLSUN777, anion far infrared powder JLSUN99 and the like, and is in close contact friction with skins to supplement and regulate multiple elements of human bodies unwittingly and naturally when people wear the underwear through skin percolation and absorption, thereby regulating the antagonism, improving human body immunity and enhancing the human body resistance so as to effectively control and prevent the diabetes mellitus which is a refractory disease.

The invention discloses a drug for treating vitiligo, and the drug takes lithargite, sulfur, blister beetle, calomel, mercury, borneol, costustoot, cassia bark, dried alum, and the like as the raw materials and uses tea seed oil, white flour and edible white vinegar for matching to produce an ointment. The drug uses the traditional Chinese medicine with toxicity as an antidote for toxin for treating the vitiligo, and the cure rate is more than 95 percent, thereby creating a new miracle and a breakthrough in medical treatment for the vitiligo which is a stubborn skin refractory disease.

The invention relates to a nano-silver anion far infrared fiber fabric wide waistband for preventing and treating nephritis and belongs to the technical field of production of healthy fiber textile fabric wide waistbands for preventing and treating the nephritis. The nephritis comprises acute and chronic nephritis, glomerulonephritis and the like, belongs to one of diseases which are difficult to treat clinically and is caused by bacterial viruses or immunological diseases. The anion far infrared fiber fabric wide waistband is prepared by automatically generating anions with a sliver antibacterial agent after being subjected to the traditional Chinese medicinal preparation nano technique and then releasing trace element nano-selenium mixed materials, and has good effects of preventing and treating various kidney diseases through skin penetration and absorption.

An objective of the present invention is to provide methods for producing progenitor cells which show a high proliferation ability ex vivo and promote neovascularization or myocardium regeneration, by culturing pluripotent cells in a medium containing adrenomedullin (AM) and / or vascular endothelial growth factor (VEGF). Moreover, another objective of the present invention is to provide the progenitor cells and uses thereof. In order to solve the above problems, the inventors of the present application have successfully developed a novel culture technique for producing progenitor cells from adipose tissues more efficiently compared to the conventional techniques, by using adrenomedullin (AM) and / or vascular endothelial growth factor (VEGF). The progenitor cells produced by the present inventors are specialized cells having a potent proliferation ability, a revascularization ability, and a myocardium regeneration ability, and have the property of not differentiating into adipocytes even if subjected to differentiation induction into adipocytes. Therefore, the progenitor cells of the present invention can be effective pharmaceutical agents for intractable diseases in the brain, lung, liver, kidney and the like.

The invention relates to a Chinese herbal medicinal wine for treating difficult and complicated miscellaneous diseases, belonging to Chinese herbal medicine field, which comprises Wooly Datchmanspipe Herb, Common Clubmoss Herb, Garden Balsam Stem, Rhizoma Ligustici, lithospermum, Lucid Ganodenma powder, Obscured Homalomena Rhizome, crab bone, Rubus phoenicolosius M-axim, plaster, actinolite, Fortune's Drynaria Rhizome and Beautiful Sweetgum Fruit. The thirteen Chinese herbal medicine are together put into 50 degrees liquor; each 650 g Chinese herbal medicine is put into 4kg of 50 degrees liquor, which is soaked for 7-15 days; and the medicine wine is obtained. The Chinese herbal medicinal wine has the advantages of pure Chinese herbal medicinal wine, no poison and side effect, significant therapeutic effect, which comprises various drug to treat femoral head necrosis, whole body muscle and bone pain caused by rheumatoid, arteriosclerosis, muscle pulse varices, innominate inflammatory, sore ganglion pain, external wound infection, red swelling, mosquitoe bite, nerve ending inflammation, beriberi, hemorrhoids, dermatosis and other various refractory diseases.

The invention provides a traditional Chinese medicine composition for treating ulcerative colitis, peptic ulcers, intestinal fistula and non-healing or chronic wounds. The active component of the traditional Chinese medicine composition is prepared from an extractive A and ganoderma spore powder extractive, wherein the extractive A is prepared by decocting and extracting the following medicinal materials in parts by weight with water: 2-12 parts of herba patriniae, 12-36 parts of semen coicis, 6-18 parts of cortex phellodendri, 6-18 parts of rhizoma corydalis, 6-18 parts of herba taraxaci, 6-18 parts of fructus toosendan and 1-9 parts of licorice roots; and in parts by weight, the amount of the ganoderma spore powder extractive is 0.5-10 parts. The composition provided by the invention provides an effective therapeutic drug for clinically treating refractory diseases including the ulcerative colitis, the intestinal fistula and the non-healing wounds, is economical and practical and has a wide clinic application prospect; and a preparation process of the composition is simple and efficient and is liable to operate and can be used for preparing granules and powder which are convenient to carry, take and locally and externally apply.

The disclosed technology relates to a method of analyzing a tissue sample. In one aspect, the method comprises obtaining a formalin-fixed paraffin-embedded (FFPE) tissue sample; contacting the tissue sample with Mung Bean Nuclease to cleave mismatched DNA pairs when isolating DNA from the tissue sample; and performing an analysis on the non-digested DNA. In one embodiment, the tissue sample is obtained from a patient having a refractory disease or a cancer during biopsy, and the analysis comprises performing next-generation DNA sequencing to evaluate genomic DNA mutations. In another embodiment, the method further comprises using a computer to screen for one or more therapies according to the cancer diagnosis; and producing a computer-generated report of possible therapies.

Disclosed is a therapeutic agent for neuropathic pain having an excellent therapeutic effect on neuropathic pain which is a intractable disease. More specifically, disclosed are a therapeutic agent for neuropathic pain which comprises a peripheral benzodiazepine receptor antagonist (particularly PK 11195) as the active ingredient; a pharmaceutical composition for the treatment of neuropathic pain which comprises a peripheral benzodiazepine receptor antagonist as the active ingredient; a method for the treatment of neuropathic pain using a peripheral benzodiazepine receptor antagonist; and others.

The invention discloses compound medicine for ulcerative colitis enema treatment. The compound medicine comprises, by weight, 15-40 parts of amur cork tree bark, 15-30 parts of garden burnet roots, 6-20 parts of rhizoma bletillae , 1-6 parts of notoginseng powder, 5-20 parts of Lithospermum erythrorhizon, 5-20 parts of folium callicarpae pedunculatae, 6-20 parts of dark plum fruits and 6-20 parts of fructus schizandrae. The invention further discloses a preparation method and application of the compound medicine. According to the preparation method, an 'internal ulcer' theory is put forward, treatment for ulcerative colitis based on external treatment of Chinese traditional medicine is innovated, systematic representation is performed in pathogenesis, treatment method, prescription and the like, and therefore a theoretical guidance effect on treatment for ulcerative colitis is achieved; the effective compound medicine is provided for the refractory disease of clinical treatment for ulcerative colitis and is economical and practical, thereby having broad clinical application prospects; the preparation method of the enema liquid is simple, quick, efficient and easy to operate, and the compound medicine is convenient to take.

The invention discloses a compound combined medicament for treating ulcerative colitis. The compound combined medicament is prepared from the following components in parts by weight: 5-40 parts of raw milkvetch root, 5-30 parts of fried largehead atractylodes rhizome, 5-40 parts of malaytea scurfpea fruit, 5-30 parts of sharpleaf galangal fruit, 5-30 parts of baical skullcap root, 1-15 parts of coptis root, 5-30 parts of garden burnet root, 3-20 parts of costus root and 1-15 parts of fried liquoric root. The invention also discloses a preparation method of the compound combined medicament for treating ulcerative colitis. The invention provides an effective therapeutic medicament for clinically treating a refractory disease namely ulcerative colitis, and the medicament is economical and practical and has a broad clinical application prospect; and the preparation method of the medicament is simple, quick, efficient, and easy to operate, and the medicament is prepared into tablets, capsules and granules to facilitate taking.

The invention discloses a compound combination medicine for treating ulcerative colitis, which comprises the following components in parts by weight: 2-9 parts of Coptis rhizome, 6-15 parts of Scutellaria baicalensis, 10-30 parts of Patrinia, 6-30 parts of fried angelica 20 parts, 5-20 parts of fried white peony, 5-15 parts of raw Burnet, 5-20 parts of comfrey, 5-15 parts of madder, 6-15 parts of Angelica dahurica, 3-12 parts of simmering wood fragrance, 2-6 parts of raw licorice share. The invention also discloses the preparation method and application of the compound medicine. The present invention provides an effective therapeutic drug for the clinical treatment of ulcerative colitis, an intractable disease, and is economical and practical, and has broad clinical application prospects; its preparation method is simple, fast, efficient, easy to operate, and the prepared granules are portable and convenient. take.

The invention provides a composition prepared from ceftriaxone sodium and sulbactam sodium as well as a medicinal preparation containing the composition and application thereof. The composition is characterized in that an X-ray powder diffraction analysis spectrum includes a specific diffraction range. The medicinal preparation containing the composition, which is provided by the invention, has better bacteriostatic activity and stability, therefore, is quite suitably used for the treatment of a bacterial infection, and particularly applicable to the treatment of a refractory disease which is caused by neisseria gonorrhoeae drug-fast to multiple antibiotics (beta-lactam, tetracycline, macrolide, fluoroquinolone or aminoglycoside) and infects a urogenital system.

The invention belongs to the biomedical field, and mainly relates to application of growth hormone releasing hormone receptor agonist MR-409 in preparation of drugs for preventing and treating ischemic brain infarction. The MR-409 is a novel GHRH receptor agonist, and preliminary researches prove that the MR-409 is capable of reducing pathological injury of refractory diseases such as diabetes mellitus and myocardial ischemia by increasing survival of multiple bone marrow stem cells in an ischemic focus. Researches in the invention prove that the MR-409 is capable of remarkably improving ischemic brain injury, survival rate and neurobehavioral manifestations of model mice with cerebral ischemia possibly through a mechanism of increasing proliferation, migration and survival of endogenous neural stem cells. The researches provide new strategies for treatment of the cerebral ischemia, have important clinic treatment significances and provide scientific and theoretical foundations for research and development of drugs utilizing regeneration of nerve cells as cerebral ischemia treating targets in future.

The invention discloses a formula for preventing and treating digestive system diseases. The formula comprises the following 13 raw materials: specially-made processed semen crotonis, specially-made rhizoma paridis powder, radix aristolochiae yunnanensis, fructus amomi, radix et caulis opuntiae dillenii, radix clematidis, resina ferulae, rhizoma atractylodis macrocephalae, rhizoma coptidis, radix notoginseng, fructus amomi rotundus and poria cocos. By the formula, toxins in human bodies can be eliminated, bacterial infection is controlled, normal physiological functions of digestive systems, such as gastrointestinal functions, liver functions, endocrine functions and the like, can be maintained, nutrient balance can be regulated, common diseases of the digestive systems can be timely cured, and conversion from common diseases to refractory diseases is effectively controlled; and the formula can be prepared into different types of liquid medicines according to requirements, and is convenient to popularize, sources of used traditional Chinese medicinal materials are sufficient, the used traditional Chinese medicinal materials are easy to purchase, utilization rate of medicinal raw materials is high, and thus, the formula is favorable for popularization.

The invention relates to the technical field of medicines, in particular to a prostatitis drug as well as a preparation method and an application thereof. The prostatitis drug comprises the following raw materials in parts by weight: 10-15 parts of semen coicis, 5-10 parts of herba patriniae, 10-15 parts of wolfberry fruit, 10-15 parts of glossy privet fruit, 10-15 parts of radix polygonati officinalis and 10-20 parts of astragalus mongholicus. The prostatitis drug is based on a traditional Chinese medicine theory and a classical prescription, is ingenious in legislation and moderate for the selected materials, has the effects of clearing heat, promoting diuresis, avoiding damage to vital energy, benefiting vital energy, nourishing yin and not helping evil retention, adopts most of medicinal and edible materials as the raw materials, and also has the effects of attacking evil in the nourishing process, gradually eliminating evil, gradually regaining health, and gradually treating refractory diseases. The prepared prostatitis drug has the characteristics of quick action, remarkable effect, safety for use and suitability for long-term use in the aspect of treating the prostatitis or / and prostatic hyperplasia, and increases the healing rate of the prostatitis or / and the prostatic hyperplasia.

Glutamine antagonists and their use for treating oncological, immunological, and neurological diseases are disclosed. Also disclosed are methods for treating an oncological, immunological, infectiousor neurological disease or disorder, the method comprising administering to a subject in need of treatment thereof a therapeutically effective amount of a glutamine antagonist of the disclosure or thepharmaceutical composition thereof. Also disclosed are methods of enhancing the effects of an immune checkpoint inhibitor, enabling a subject to respond to an immune checkpoint inhibitor, or enablingthe toxicity or the dose or number of treatments with an immune checkpoint inhibitor to be reduced, comprising administering to a subject in need of treatment thereof a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof, and an immune checkpoint inhibitor. Also disclosed are methods for treating an oncological, immunological, infectious or neurological disease or disorder that is refractory to checkpoint inhibitor therapy, the method comprising administering to a subject in need thereof, and having the refractory disease or disorder, a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof.

The present invention provides a therapeutic agent for neuropathic pain having an excellent treating effect on neuropathic pain, which is an intractable disorder. More specifically, the present invention provides a therapeutic agent for neuropathic pain and a pharmaceutical composition for treating neuropathic pain, comprising (1) a compound having an anti-progesterone activity (for example, fulvestrant (ICI182.780), fluocinolone acetonide, triamcinolone acetonide, etc.), (2) a compound having an estrogen activity (for example, 17β-estradiol), or (3) a mixture of a compound having an anti-progesterone activity and a compound having an estrogen activity (for example, 17β-estradiol and fulvestrant), as an active ingredient; a method for treating neuropathic pain using such a compound, and the like.

The present invention provides a therapeutic agent for a lower urinary tract disease such as cystitis, interstitial cystitis, prostatitis, benign prostatic hyperplasia etc., which are considered as refractory disease, and an agent for improving a lower urinary tract symptom associated with the lower urinary tract disease.